EUCTR2005-003337-40-BE进行中（未招募）不适用
A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
未提供0 个研究点开始时间: 2010年5月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- age between 18 and 50 years
- •- confirmed diagnosis of active Crohn's Disease
- •- unsatisfactory course despite 3 immunosuppressive agents in addition to corticosteroids
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- BMI < 18
- •- concomitant severe disease
- •- infection
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-GBovartis Pharmaceuticals UK Ltd446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung cancerPrevention of bone metastasis in patients with non small cell lung cancer Stage III.MedDRA version: 6.1Level: PTClassification code 10029519EUCTR2004-001101-10-ITOVARTIS FARMA
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerEUCTR2004-001101-10-HUovartis Pharma Services AG446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-BEovartis Pharma Services AG446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-ATovartis Pharma Services AG446